Multiple Myeloma

CAR T-Cell Immunotherapy Makes Strides in Multiple Myeloma, with Durable Remission

Chicago, IL—The era of immunotherapy in multiple myeloma is near. Two presentations at ASCO 2017 demonstrated that cellular therapy can steer immune reconstitution against multiple myeloma. Edward A. Stadtmauer, MD, Chief, Hematologic Malignancies Section, Abramson Cancer Center, University of Pennsylvania, Philadelphia, reviewed cellular strategies, from vaccine-primed T-cell transfer after autologous [ Read More ]

Daratumumab Added to Carfilzomib, Lenalidomide, and Dexamethasone: Safe and Tolerable in Patients with Newly Diagnosed Multiple Myeloma

Chicago, IL—In patients with newly diagnosed multiple myeloma, the addition of daratumumab to carfilzomib (Kyprolis), lenalidomide (Revlimid), and dexamethasone (ie, the KRd regimen) is showing promise as a frontline treatment regimen. According to the results of an open-label, phase 1b study presented at ASCO 2017, induction therapy with the KRd [ Read More ]

Lenalidomide plus Elotuzumab Maintenance Regimen Improves Responses in Multiple Myeloma

Atlanta, GA—A maintenance regimen of lenalidomide (Revlimid) and elotuzumab (Empliciti) after autologous stem-cell transplant (ASCT) improved the quality of responses achieved with induction therapy in patients with multiple myeloma. In a phase 2 study, 36% of patients receiving the combination as maintenance showed an improvement in response, and 20% of [ Read More ]

Daratumumab Therapy for Smoldering Myeloma Extends Progression-Free Survival

Atlanta, GA—Single-agent daratum­umab (Darzalex) shows significant activity in smoldering multiple myeloma (SMM). The 12-month progression-free survival (PFS) rate with a long dosing schedule of daratumumab was 95%, and the median PFS was not yet reached in any of the 3 dosing schedules studied, announced Craig C. Hofmeister, MD, MPH, Associate [ Read More ]

Sign me up!